Pharma BD Deal Intelligence
BioNTech acquired Kite's individualized solid-tumor neoantigen TCR discovery platform and clinical manufacturing facility in Gaithersburg, MD, from Gilead. Announced July 19, 2021 and closed August 4, 2021; financial terms were not disclosed, with BioNTech later citing ~$250M in associated transaction costs (Q3 2021). The deal gave BioNTech a TCR-based cell-therapy capability and its first U.S. manufacturing footprint to pair with its mRNA cancer-vaccine platforms, while letting Gilead's Kite refocus on hematologic CAR-T (Yescarta, Tecartus). Post-close outcome: in June 2025 BioNTech announced it would cease cell-therapy manufacturing at the Gaithersburg site by end of 2025 and lay off 63 technical-operations staff, after dropping its lead CLDN6 CAR-T candidate BNT211 in germ-cell/testicular tumors following a Phase 1 signal-seeking readout. BNT211 development continues in other CLDN6-positive solid tumors, and the site is being realigned to other portfolio priorities (including ADCs such as BNT323), reflecting BioNTech's strategic pivot away from cell therapy toward mRNA and antibody-drug-conjugate modalities.